BYETTA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BYETTA (BYETTA).
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes satiety.
| Metabolism | Exenatide is primarily cleared by glomerular filtration and proteolytic degradation, with minimal hepatic metabolism by dipeptidyl peptidase-4 (DPP-4). |
| Excretion | Primarily renal; intact drug eliminated in urine (approximately 80% of the dose). Minor biliary/fecal excretion accounts for <10%. |
| Half-life | Terminal elimination half-life 2.4 hours; provides clinical duration of action supporting twice-daily dosing. |
| Protein binding | Approximately 60% bound to plasma proteins (albumin). |
| Volume of Distribution | Apparent volume of distribution 28 L (0.4 L/kg); indicates limited extravascular distribution. |
| Bioavailability | Subcutaneous: 65–75% after abdominal, thigh, or arm injection. |
| Onset of Action | Subcutaneous: Onset within 1 hour; peak effect on gastric emptying and glucagon suppression at 2–3 hours. |
| Duration of Action | Duration of action approximately 10 hours after subcutaneous injection; supports twice-daily administration. |
5 mcg subcutaneously twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month if tolerated.
| Dosage form | INJECTABLE |
| Renal impairment | eGFR 30-50 mL/min: use with caution; eGFR <30 mL/min: not recommended. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B); not studied in severe impairment (Child-Pugh class C). |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor renal function and use caution due to increased risk of gastrointestinal effects and hypoglycemia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BYETTA (BYETTA).
| Breastfeeding | Excreted in milk in animals; unknown in humans. M/P ratio not established. Caution advised; consider alternative therapies due to lack of safety data. |
| Teratogenic Risk | Pregnancy Category C. In animal studies, exenatide has been associated with reduced fetal growth and skeletal ossification at high doses. No adequate human studies exist. Risk cannot be ruled out; use only if benefit justifies potential risk. First trimester: unknown risk; second/third trimester: monitor for fetal growth abnormalities. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Personal or family history of medullary thyroid carcinoma (MTC)","Multiple endocrine neoplasia syndrome type 2 (MEN-2)","Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease","Known hypersensitivity to exenatide or any product components"]
| Precautions | ["Risk of acute pancreatitis (discontinue if suspected)","Renal impairment (contraindicated in severe renal impairment or end-stage renal disease)","Severe gastrointestinal disease (may exacerbate gastroparesis)","Hypoglycemia when used with insulin secretagogues or insulin","Thyroid C-cell tumors (observed in animal studies, relevance unknown)","Immunogenicity and antibody formation","Increased heart rate and potential for cardiac adverse events"] |
| Food/Dietary | BYETTA slows gastric emptying; thus, the absorption of oral medications (e.g., oral contraceptives, antibiotics) may be reduced. Take oral contraceptives at least 1 hour before BYETTA or at least 4 hours after. No specific food restrictions, but starting with a low-fat diet may help minimize gastrointestinal side effects. High-fat meals may exacerbate nausea and vomiting. Avoid grapefruit juice? No known interaction. Caution with alcohol due to hypoglycemia risk. |
Loading safety data…
| Monitor blood glucose and HbA1c, fetal growth via ultrasound, maternal weight gain, renal function, and signs of pancreatitis or hypoglycemia. |
| Fertility Effects | Animal studies show no impairment of fertility at clinically relevant doses. No human data on fertility effects. |
| Clinical Pearls | BYETTA (exenatide) is a GLP-1 receptor agonist used as adjunct to diet and exercise for type 2 diabetes. It slows gastric emptying, which can cause nausea and vomiting, especially upon initiation. Administer subcutaneously within 60 minutes before morning and evening meals. Avoid in patients with severe renal impairment (CrCl <30 mL/min) or history of pancreatitis. Monitor for acute pancreatitis if severe abdominal pain occurs. Not indicated for type 1 diabetes or DKA. Discontinue prior to surgery if prolonged fasting is required. May cause weight loss. Do not use with insulin (except possibly basal insulin). |
| Patient Advice | Inject BYETTA within 60 minutes before your two main meals, at least 6 hours apart. Do not inject after a meal. · Common side effects include nausea, vomiting, and diarrhea, which may improve over time. Take small, low-fat meals to reduce nausea. · Seek medical attention immediately if you experience severe abdominal pain (possible pancreatitis) or allergic reactions (rash, swelling, difficulty breathing). · BYETTA can cause weight loss and may be used with diet and exercise. Do not stop or adjust your diabetes medications without consulting your doctor. · Store unused pens in the refrigerator (36°F to 46°F). Do not freeze. Once in use, store at room temperature (not above 77°F) for up to 30 days. · Do not share your pen with others even if you change the needle. Use a new needle for each dose. · Avoid alcohol as it may increase the risk of hypoglycemia. Take your missed dose within 60 minutes of your next meal; otherwise skip it. |